| abstract |
This invention is directed, in part, to solid amorphous and crystalline forms of (2S, 3R, 4R, 5S, 6R) -2- (4-chloro-3- (4-ethoxybenzyl) phenyl) -6- (methylthio) tetrahydro Anhydrous -2H-pyran-3,4,5-triol, which is a type 2 sodium glucose co-transporter inhibitor, and may be useful in the treatment of diabetes and a variety of other diseases and conditions. This invention is also directed to dosage forms comprising solid forms of (2S, 3R, 4R, 5S, 6R) -2- (4-chloro-3- (4-ethoxybenzyl) phenyl) -6- (methylthio) tetrahydro- 2H-piran-3,4,5-triol anhydrous, and with methods for its use. An embodiment of the invention encompasses pharmaceutical compositions comprising the solid forms described herein. Another embodiment encompasses methods for inhibiting SGLT2 activity, as well as methods to treat, prevent and manage a variety of diseases and disorders, using the solid forms described here. |